Japan's Kissei Pharmaceutical reported 20 deaths among patients taking the vasculitis drug Tavneos, manufactured in the US.
The company warned against prescribing the drug due to severe liver damage and is consulting with Japan's Health Ministry.
About 8,500 patients have used the drug since 2022. The FDA plans to revoke its US registration due to efficacy concerns.












